Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | X5T42 | — |
painful rash developing on the arm two weeks after administration of Shingrix first dose.; painful rash developing on the arm two weeks after administration of Shingrix first dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of rash in a 82-year-old female patient who received Herpes zoster (Shingrix) (batch number X5T42, expiry date 30-JAN-2027) for prophylaxis. On 14-FEB-2025, the patient received the 1st dose of Shingrix. In FEB-2025, 2 weeks after receiving Shingrix, the patient experienced rash (Verbatim: painful rash developing on the arm two weeks after administration of Shingrix first dose.) and pain (Verbatim: painful rash developing on the arm two weeks after administration of Shingrix first dose). The outcome of the rash and pain were unknown. It was unknown if the reporter considered the rash and pain to be related to Shingrix. It was unknown if the company considered the rash and pain to be related to Shingrix. Additional Information: GSK Receipt Date: 28-FEB-2025 Pharmacist reported that a patient had a painful rash developing on the arm two weeks after administration of Shingrix. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up.